We are developing a drug to burn calories and increase metabolism…
Public company, workplace, funding, and market signals
Updated Jul 30, 2026
Equator Therapeutics is a biotechnology research company developing first-in-class small-molecule therapeutics that stimulate mitochondrial thermogenesis to increase energy expenditure and treat obesity and other metabolic disorders.
Primary product
First-in-class mitochondrial thermogenesis drug program for obesity and metabolic disorders
Founded
2020
Headquarters
San Francisco, California, United States
Team size
1-10
Industry
Biotechnology Research
Sub-industry
Metabolic disorders therapeutics / mitochondrial drug discovery
Offices
0 jobs at Equator Therapeutics
Check back later for new openings
Business model
Stage
venture
Total raised
$650K
Latest round
Venture Round · Jan 2022
Latest amount
$500K
Jan 2022 · Alameda Research
Jan 2021
Mar 2020
Leadership
Co-founder, CEO
Co-founder, Chief Scientific Officer
Head of Medicinal Chemistry
Advisor; directs Japan branch
Founders
Co-founder, Senior Scientist
Investors
Public commentary depicts a lean, cautious, data-driven culture that stresses intellectual honesty, stress-testing results, and avoiding overselling early data.
Differentiators
Technology
Competitors
Estimated revenue
$1M-$10M
Estimated monthly visits
48
Endurance28 · Oct 2025
Profiles CEO/co-founder Jonah Sinick and describes Equator as a lean five-person team with a culture centered on intellectual honesty, careful data validation, and cautious fundraising amid grant delays and shifting policy conditions.
Bakar Bio Labs · Feb 2025
Event recap noting that Equator Therapeutics founders presented their work and team to the Bakar Bio Labs community.
SBIR.gov · Jul 2024
NIH SBIR Phase II award for Equator Therapeutics, describing the company’s first-in-class mitochondrial thermogenesis program and a $3.14M award amount.